Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 27 Sep 2026 · Editorial standards

At a glance

Anhui Provincial Hospital is the lead sponsor of 56 current clinical trials in our China register. 44 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Adebrelimab, Avatrombopag and Basiliximab. The most-studied condition is Esophageal Squamous Cell Carcinoma.

ClinicalTrials.gov trials by status

Recruiting4479%
Not yet open814%
Active, closed35%
By invitation12%

Trials by phase

Observational1934%
Not applicable1018%
Phase 21018%
Phase EARLY_PHASE159%
Phase 159%
Phase 335%
Phase 1/224%
Phase 424%

Clinical trials sponsored by Anhui Provincial Hospital

56 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer NCT06737588 · Prostate Cancer	Observational	Recruiting	2024-12	China
Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma NCT05833594 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition	Observational	Recruiting	2023-07	China
Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia NCT06973356 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia (ITP)	Not applicable	Recruiting	2025-08	China
Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery NCT06673498 · ClinicalTrials.gov ↗ · Thrombocytopenia Drugs: Lusutrombopag, Recombinant human thrombopoietin	Phase 2	Recruiting	2024-11	China
Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer NCT06527898 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer	Phase 1/2	Recruiting	2024-07	China
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases NCT07121777 · ClinicalTrials.gov ↗ · Autoimmune Diseases	Not applicable	Recruiting	2025-08	China
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine NCT07150624 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Liver Diseases	Phase 4	Recruiting	2025-11	China
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis NCT06756334 · ClinicalTrials.gov ↗ · Prostate Cancer, PET/CT	Phase EARLY_PHASE1	Recruiting	2024-12	China
Anti CD19 Gene Therapy for B-cell Lymphoma NCT07211048 · ClinicalTrials.gov ↗ · B-cell Lymphoma	Not applicable	Recruiting	2026-03	China
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma NCT06961669 · ClinicalTrials.gov ↗ · Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM)	Not applicable	Recruiting	2025-04	China
CAR-T Cells Therapy for Patients With Autoimmune Diseases NCT07052565 · ClinicalTrials.gov ↗ · Autoimmune Diseases	Not applicable	Recruiting	2025-07	China
Artificial Intelligence for Pathology Diagnosis and Prognosis Prediction of Lung Nodule Using Smartphone Photos NCT07098884 · ClinicalTrials.gov ↗ · Artificial Intelligence, Lung Nodule	Observational	Recruiting	2025-06	China
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR) NCT06232083 · ClinicalTrials.gov ↗ · Lung Cancer, Esophageal Cancer, Cervical Cancer	Phase 1	Recruiting	2025-09	China
Cervical Cancer Susceptible Population Classification NCT06405945 · ClinicalTrials.gov ↗ · Cervical Cancer Susceptible Population Classification	Observational	Recruiting	2024-05	China
The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT NCT06362967 · ClinicalTrials.gov ↗ · High Titers of Anti-HLA Antibody (MFI ≥5000)	Phase 2	Recruiting	2024-05	China
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases NCT06294691 · ClinicalTrials.gov ↗ · Acute Graft-versus-host Disease	Phase 3	Recruiting	2024-03	China
Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia NCT06898983 · ClinicalTrials.gov ↗ · Cancer Treatment-induced Thrombocytopenia (CTIT) Drug: Romiplostim N01	Phase 2	Recruiting	2025-07	China
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT NCT07047456 · ClinicalTrials.gov ↗ · Acute Graft Versus Host Disease	Phase 3	Recruiting	2025-07	China
The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia NCT06307600 · ClinicalTrials.gov ↗ · B Lymphoblastic Leukemia/Lymphoma Drug: RD06	Phase EARLY_PHASE1	Recruiting	2024-03	China
China Liver Cancer Clinical Registry Cohort Database (HEAL) NCT06777485 · ClinicalTrials.gov ↗ · Liver Cancer	Observational	Recruiting	2025-01	China
Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT NCT06693791 · ClinicalTrials.gov ↗ · Platelet Recovery After Umbilical Cord Blood Transplantation	Phase 2	Recruiting	2024-12	China
Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab NCT06408584 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Observational	Recruiting	2024-03	China
Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease NCT05823376 · ClinicalTrials.gov ↗ · Platelet Recovery After Umbilical Cord Blood Transplantation Drug: Avatrombopag	Observational	Recruiting	2023-05	China
Reconstruction Kinetics of γδ T Cells After Unrelated Cord Blood Transplantation NCT07782684 · ClinicalTrials.gov ↗ · Hematologic Disease and Disorders	Observational	Recruiting	2025-10	China
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma NCT05937438 · ClinicalTrials.gov ↗ · Esophageal Carcinoma	Phase 1/2	Recruiting	2023-09	China
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma NCT07188103 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drug: Ivonescimab	Phase 2	Recruiting	2025-07	China
Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors NCT07106814 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase EARLY_PHASE1	Recruiting	2025-08	China
Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation NCT07830576 · ClinicalTrials.gov ↗ · Colorectal Liver Metastases, Colorectal Neoplasms, Liver Neoplasms	Observational	Recruiting	2017-02	China
Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer NCT06640348 · ClinicalTrials.gov ↗ · Ovarian Cancer, Epithelial	Observational	Recruiting	2025-01	China
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor NCT07096479 · ClinicalTrials.gov ↗ · Chemotherapy-induced Neutropenia Drug: Telpegfilgrastim	Observational	Recruiting	2024-08	China
Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma NCT07793695 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	2026-09	China
Sulfamethoxazole Prophylaxis Duration After Renal Transplantation NCT07231770 · ClinicalTrials.gov ↗ · Fever, Chest Tightness	Not applicable	Recruiting	2024-05	China
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma NCT06664021 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma Drug: Tislelizumab	Phase 2	Recruiting	2024-11	China
A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD NCT06321198 · ClinicalTrials.gov ↗ · Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)	Not applicable	Recruiting	2024-02	China
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab NCT06498622 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: Donafenib, Envafolimab	Phase 2	Recruiting	2024-07	China
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research NCT07085559 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM), Plasma Cell Leukemia (PCL), AL Amyloidosis (AL)	Phase EARLY_PHASE1	Recruiting	2025-06	China
China Metastatic Liver Cancer Clinical Registry Cohort Database NCT07602504 · ClinicalTrials.gov ↗ · Liver Metastases, Metastases to Liver, Liver Cancer	Observational	Recruiting	2026-06	China
The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT NCT06558253 · ClinicalTrials.gov ↗ · Hematopoietic Recovery Drug: Coenzyme I	Phase 1	Recruiting	2024-11	China
Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma NCT07782632 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Observational	Recruiting	2019-01	China
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy NCT06602843 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Not applicable	Recruiting	2024-01	China
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases NCT06449937 · ClinicalTrials.gov ↗ · Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer, Metastatic Malignant Neoplasm in the Liver	Not applicable	Recruiting	2024-07	China
An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy NCT06151028 · ClinicalTrials.gov ↗ · Gynecological Malignancies, Menopausal Symptoms, Bone Loss	Observational	Recruiting	2023-12	China
Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer NCT06612047 · ClinicalTrials.gov ↗ · Prostate Cancer	Observational	Recruiting	2024-10	China
Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease NCT07208344 · ClinicalTrials.gov ↗ · Alzheimer Disease (AD) Drug: Galantamine	Phase EARLY_PHASE1	Recruiting	2025-07	China
Postoperative ctHPV-DNA for Recurrence Prediction and Adjuvant Treatment Decision-Making in Cervical Cancer NCT07782697 · ClinicalTrials.gov ↗ · Cervical Cancer, HPV DNA	Observational	Not yet open	2026-09	China
Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases NCT06480630 · ClinicalTrials.gov ↗ · Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm Drug: Basiliximab	Phase 2	Not yet open	2024-07	China
Perioperative Adebrelimab for Locally Advanced Cervical Cancer NCT07811375 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer Drugs: Adebrelimab, Carboplatin, Cisplatin	Phase 2	Not yet open	2026-10	China
Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study NCT07034118 · ClinicalTrials.gov ↗ · Esophageal Carcinoma	Phase 1	Not yet open	2025-08	China
A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites NCT06415500 · ClinicalTrials.gov ↗ · Gynecologic Cancer	Phase 1	Not yet open	2024-05	China
Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT. NCT07462676 · ClinicalTrials.gov ↗ · Ventriculoperitoneal Shunt (VPS), Cranioplasty	Not applicable	Not yet open	2026-04	China
Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines NCT07077980 · ClinicalTrials.gov ↗ · Cervical Cancer	Observational	Not yet open	2025-09	China
Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) NCT07481656 · ClinicalTrials.gov ↗ · Acute Brain Injuries, Moderate to Severe Traumatic Brain Injury	Phase 4	Not yet open	2026-04	China
A Clinical Study to Evaluate CUD005 Injection in Patients with Liver Cirrhosis NCT06671275 · ClinicalTrials.gov ↗ · Cirrhosis Liver	Phase 1	By invitation	2024-06	China
Observational, Bivariate Analysis of Clinical Big Data in Patients With Cervical Cancer NCT06480617 · ClinicalTrials.gov ↗ · Progression-free Survival Was Defined From Date of Surgery to Disease Progression Post-surgery or Death or Last Follow-up, Overall Survival Was Defined as Time From Surgery to Death From Any Cause or Last Follow-up	Observational	Active, closed	2023-10	China
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies NCT06294678 · ClinicalTrials.gov ↗ · Acute Graft-versus-host Disease	Phase 3	Active, closed	2024-03	China
Mesenteric Lymph Node Metastasis and Nutritional Status After Bowel Resection for Ovarian Cancer NCT06527001 · ClinicalTrials.gov ↗ · Progression-Free Survival, Overall Survival, Nutrition Aspect of Cancer	Observational	Active, closed	2024-06	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Anhui Provincial Hospital trials

17 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Adebrelimab1 Avatrombopag1 Basiliximab1 Carboplatin1 Cisplatin1 Coenzyme I1 Donafenib1 Envafolimab1 Galantamine1 Ivonescimab1 Lusutrombopag1 Paclitaxel1 RD061 Recombinant human thrombopoietin1 Romiplostim N011 Telpegfilgrastim1 Tislelizumab1

Conditions in Anhui Provincial Hospital trials

69 conditions

Esophageal Squamous Cell Carcinoma4 Prostate Cancer3 Cervical Cancer3 Autoimmune Diseases2 Hepatocellular Carcinoma (HCC)2 Acute Graft-versus-host Disease2 Acute Graft Versus Host Disease2 Liver Cancer2Platelet Recovery After Umbilical Cord Blood Transplantation2Esophageal Carcinoma2 Hepatocellular Carcinoma2 Chemoradiotherapy1Immunonutrition1Inoperable1Immune Thrombocytopenia (ITP)1 Thrombocytopenia1 Small-cell Lung Cancer1Liver Diseases1HPV DNA1PET/CT1 B-cell Lymphoma1Lymphoblastic Leukemia1Relapsed or Refractory Multiple Myeloma (RRMM)1Artificial Intelligence1

By trial register

Register	Trials	Recruiting
Clinical trials in China	56	44

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Esophageal Squamous Cell Carcinoma

Sponsor	Trials
Peking University	5
Hebei Medical University Fourth Hospital	4
Tang-Du Hospital	4
Shanghai Zhongshan Hospital	4
Zhejiang Cancer Hospital	3
Fujian Medical University Union Hospital	3
Sichuan Cancer Hospital and Research Institute	2
Shandong Boan Biotechnology	1
Affiliated Cancer Hospital of Shantou University Medical College	1
Zhigang Li	1

Sponsors with the most current trials registered for this condition.

Questions about Anhui Provincial Hospital trials

How many clinical trials does Anhui Provincial Hospital sponsor?

Anhui Provincial Hospital is the lead sponsor of 56 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Anhui Provincial Hospital trials recruiting?

Yes. 44 of its 56 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Anhui Provincial Hospital testing?

Its current trials name 17 drugs and biologicals as interventions. The most frequent are Adebrelimab (1), Avatrombopag (1), Basiliximab (1), Carboplatin (1) and Cisplatin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Anhui Provincial Hospital clinical trials